Which medication is used for Pediatric Unstable Polymorphic VT after defibrillation attempts?

Which medication is used for Pediatric Unstable Polymorphic VT after defibrillation attempts?

• A. Magnesium Sulfate 40 mg/kg IV/IO
• B. Epinerphrine 1 mg IV
• C. Amiodarone 150 mg
• D. Lidocaine 1 mg/kg

Answer: (A)

Magnesium sulfate is used for unstable polymorphic VT in children after defibrillation attempts because this rhythm often represents torsades de pointes, which is driven by QT prolongation and abnormal calcium influx. Giving magnesium helps stabilize the cardiac membranes, reduces early afterdepolarisations, and lowers the likelihood of continued ectopic activity that sustains the polymorphic VT. It can be effective even if serum magnesium is normal, and it specifically targets the mechanism behind torsades rather than just suppressing rhythm non-specifically. The typical pediatric dose for this scenario is 25-50 mg/kg IV/IO, up to a maximum of about 2 g. A dose of 40 mg/kg falls within this recommended range and is commonly used in resuscitation when torsades is suspected. Why the others are not the best fit here: epinephrine is focused on improving perfusion during CPR but does not terminate torsades itself; amiodarone is a broad antiarrhythmic useful for VT/VF in many contexts but torsades responds best to magnesium; lidocaine can be used for VT in some cases but is not the preferred treatment for torsades, and it doesn’t address the underlying mechanism as effectively as magnesium in this scenario. In short, when faced with unstable polymorphic VT after defibrillation in a pediatric patient, magnesium sulfate is the appropriate, mechanism-targeted choice.

Magnesium sulfate is used for unstable polymorphic VT in children after defibrillation attempts because this rhythm often represents torsades de pointes, which is driven by QT prolongation and abnormal calcium influx. Giving magnesium helps stabilize the cardiac membranes, reduces early afterdepolarisations, and lowers the likelihood of continued ectopic activity that sustains the polymorphic VT. It can be effective even if serum magnesium is normal, and it specifically targets the mechanism behind torsades rather than just suppressing rhythm non-specifically.

The typical pediatric dose for this scenario is 25-50 mg/kg IV/IO, up to a maximum of about 2 g. A dose of 40 mg/kg falls within this recommended range and is commonly used in resuscitation when torsades is suspected.

Why the others are not the best fit here: epinephrine is focused on improving perfusion during CPR but does not terminate torsades itself; amiodarone is a broad antiarrhythmic useful for VT/VF in many contexts but torsades responds best to magnesium; lidocaine can be used for VT in some cases but is not the preferred treatment for torsades, and it doesn’t address the underlying mechanism as effectively as magnesium in this scenario.

In short, when faced with unstable polymorphic VT after defibrillation in a pediatric patient, magnesium sulfate is the appropriate, mechanism-targeted choice.